SGLT2 inhibitors gained popularity after the EMPA-REG OUTCOME research revealed a reduced risk of major CV events or mortality in high-risk T2DM patients with empagliflozin added to their conventional treatment [9]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.